Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA (original) (raw)

References

  1. Diaz, L. A., Jr et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 486, 537–540 (2012)
    Article ADS CAS PubMed PubMed Central Google Scholar
  2. Aparicio, S. & Caldas, C. The implications of clonal genome evolution for cancer medicine. N. Engl. J. Med. 368, 842–851 (2013)
    Article CAS PubMed Google Scholar
  3. Gerlinger, M. et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366, 883–892 (2012)
    Article CAS PubMed PubMed Central Google Scholar
  4. Shah, S. P. et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 486, 395–399 (2012)
    Article ADS CAS PubMed Google Scholar
  5. Chan, K. C. et al. Cancer genome scanning in plasma: detection of tumor-associated copy number aberrations, single-nucleotide variants, and tumoral heterogeneity by massively parallel sequencing. Clin. Chem. 59, 211–224 (2013)
    Article CAS PubMed Google Scholar
  6. Forshew, T. et al. Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci. Transl. Med. 4, 136ra168 (2012)
    Article Google Scholar
  7. Leary, R. J. et al. Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing. Sci. Transl. Med. 4, 162ra154 (2012)
    Article PubMed PubMed Central Google Scholar
  8. Isakoff, S. J. et al. Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. Cancer Res. 65, 10992–11000 (2005)
    Article CAS PubMed Google Scholar
  9. Knudsen, E. S. & Knudsen, K. E. Tailoring to RB: tumour suppressor status and therapeutic response. Nature Rev. Cancer 8, 714–724 (2008)
    Article CAS Google Scholar
  10. Cui, J. et al. Cross-talk between HER2 and MED1 regulates tamoxifen resistance of human breast cancer cells. Cancer Res. 72, 5625–5634 (2012)
    Article CAS PubMed PubMed Central Google Scholar
  11. Nagalingam, A. et al. Med1 plays a critical role in the development of tamoxifen resistance. Carcinogenesis 33, 918–930 (2012)
    Article CAS PubMed PubMed Central Google Scholar
  12. Liu, L. et al. Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL. Cancer Res. 69, 6871–6878 (2009)
    Article CAS PubMed Google Scholar
  13. Zhang, Z. et al. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nature Genet. 44, 852–860 (2012)
    Article CAS PubMed Google Scholar
  14. Pao, W. et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2, e73 (2005)
    Article PubMed PubMed Central Google Scholar
  15. Punnoose, E. A. et al. Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib. Clin. Cancer Res. 18, 2391–2401 (2012)
    Article CAS PubMed Google Scholar
  16. Diehl, F. et al. Circulating mutant DNA to assess tumor dynamics. Nature Med. 14, 985–990 (2008)
    Article ADS CAS PubMed Google Scholar
  17. McBride, D. J. et al. Use of cancer-specific genomic rearrangements to quantify disease burden in plasma from patients with solid tumors. Genes Chromosom. Cancer 49, 1062–1069 (2010)
    Article CAS PubMed Google Scholar
  18. Yung, T. K. et al. Single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non-small cell lung cancer patients. Clin. Cancer Res. 15, 2076–2084 (2009)
    Article CAS PubMed Google Scholar
  19. Lo, Y. M. et al. Maternal plasma DNA sequencing reveals the genome-wide genetic and mutational profile of the fetus. Sci. Transl. Med. 2, 61ra91 (2010)
    Article CAS PubMed Google Scholar
  20. Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25, 1754–1760 (2009)
    Article CAS PubMed PubMed Central Google Scholar
  21. DePristo, M. A. et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nature Genet. 43, 491–498 (2011)
    Article CAS PubMed Google Scholar
  22. Li, H. et al. The sequence alignment/map format and SAMtools. Bioinformatics 25, 2078–2079 (2009)
    Article PubMed PubMed Central Google Scholar
  23. Wang, K., Li, M. & Hakonarson, H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 38, e164 (2010)
    Article PubMed PubMed Central Google Scholar
  24. Diehl, F. et al. Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc. Natl Acad. Sci. USA 102, 16368–16373 (2005)
    Article ADS CAS PubMed PubMed Central Google Scholar
  25. Siddique, H. R. & Saleem, M. Role of BMI1, a stem cell factor, in cancer recurrence and chemoresistance: preclinical and clinical evidences. Stem Cells 30, 372–378 (2012)
    Article CAS PubMed Google Scholar
  26. Chang, H. et al. Identification of genes associated with chemosensitivity to SAHA/taxane combination treatment in taxane-resistant breast cancer cells. Breast Cancer Res. Treat. 125, 55–63 (2011)
    Article CAS PubMed Google Scholar
  27. Sato, K. et al. Histone chaperone activity of Fanconi anemia proteins, FANCD2 and FANCI, is required for DNA crosslink repair. EMBO J. 31, 3524–3536 (2012)
    Article CAS PubMed PubMed Central Google Scholar
  28. Haslehurst, A. M. et al. EMT transcription factors snail and slug directly contribute to cisplatin resistance in ovarian cancer. BMC Cancer 12, 91 (2012)
    Article CAS PubMed PubMed Central Google Scholar
  29. VanderWeele, D. J., Zhou, R. & Rudin, C. M. Akt up-regulation increases resistance to microtubule-directed chemotherapeutic agents through mammalian target of rapamycin. Mol. Cancer Ther. 3, 1605–1613 (2004)
    CAS PubMed Google Scholar
  30. Wu, C. C., Yu, C. T., Chang, G. C., Lai, J. M. & Hsu, S. L. Aurora-A promotes gefitinib resistance via a NF-κB signaling pathway in p53 knockdown lung cancer cells. Biochem. Biophys. Res. Commun. 405, 168–172 (2011)
    Article CAS PubMed Google Scholar

Download references

Acknowledgements

We thank J. Langmore and K. Solomon (Rubicon Genomics) for early access to library preparation products. We thank L. Jones, S. Richardson, C. Hodgkin and H. Biggs for recruiting patients into the DETECT and CTCR-OVO4 studies, all medical and ancillary staff in the breast and gynaecological cancer clinic and patients for consenting to participate. We thank the Human Research Tissue Bank at Addenbrooke’s Hospital which is supported by the NIHR Cambridge Biomedical Research Centre. We thank the Cancer Science Institute, National University of Singapore, and the Hematology-Oncology Research Group, National University Health System, Singapore for their support. We acknowledge the support of Cancer Research UK, the University of Cambridge, National Institute for Health Research Cambridge Biomedical Research Centre, Cambridge Experimental Cancer Medicine Centre, Hutchison Whampoa Limited, and the National Medical Research Council, Singapore. S.-J.D. is supported by an Australian NHMRC/RG Menzies Early Career Fellowship that is administered through the Peter MacCallum Cancer Centre, Victoria, Australia.

Author information

Author notes

  1. Muhammed Murtaza, Sarah-Jane Dawson and Dana W. Y. Tsui: These authors contributed equally to this work.

Authors and Affiliations

  1. Cancer Research UK Cambridge Institute and University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge CB2 0RE, UK,
    Muhammed Murtaza, Sarah-Jane Dawson, Dana W. Y. Tsui, Davina Gale, Tim Forshew, Anna M. Piskorz, Christine Parkinson, Suet-Feung Chin, Francesco Marass, James Hadfield, James D. Brenton, Carlos Caldas & Nitzan Rosenfeld
  2. Addenbrooke’s Hospital, Cambridge University Hospital NHS Foundation Trust and NIHR Cambridge Biomedical Research Centre, Cambridge CB2 2QQ, UK,
    Sarah-Jane Dawson, Christine Parkinson, James D. Brenton & Carlos Caldas
  3. Illumina, Inc., Chesterford Research Park, Little Chesterford CB10 1XL, UK,
    Zoya Kingsbury, Sean Humphray & David Bentley
  4. Department of Haematology-Oncology, National University Cancer Institute, National University Health System, 5 Lower Kent Ridge Road, Tower block level 7, 119074 Singapore,
    Alvin S. C. Wong & Tan Min Chin
  5. Cancer Science Institute, National University of Singapore, Centre for Translational Medicine, 14 Medical Drive, #12-01, 117599 Singapore,
    Tan Min Chin
  6. Cambridge Experimental Cancer Medicine Centre, Cambridge CB2 0RE, UK,
    James D. Brenton & Carlos Caldas

Authors

  1. Muhammed Murtaza
    You can also search for this author inPubMed Google Scholar
  2. Sarah-Jane Dawson
    You can also search for this author inPubMed Google Scholar
  3. Dana W. Y. Tsui
    You can also search for this author inPubMed Google Scholar
  4. Davina Gale
    You can also search for this author inPubMed Google Scholar
  5. Tim Forshew
    You can also search for this author inPubMed Google Scholar
  6. Anna M. Piskorz
    You can also search for this author inPubMed Google Scholar
  7. Christine Parkinson
    You can also search for this author inPubMed Google Scholar
  8. Suet-Feung Chin
    You can also search for this author inPubMed Google Scholar
  9. Zoya Kingsbury
    You can also search for this author inPubMed Google Scholar
  10. Alvin S. C. Wong
    You can also search for this author inPubMed Google Scholar
  11. Francesco Marass
    You can also search for this author inPubMed Google Scholar
  12. Sean Humphray
    You can also search for this author inPubMed Google Scholar
  13. James Hadfield
    You can also search for this author inPubMed Google Scholar
  14. David Bentley
    You can also search for this author inPubMed Google Scholar
  15. Tan Min Chin
    You can also search for this author inPubMed Google Scholar
  16. James D. Brenton
    You can also search for this author inPubMed Google Scholar
  17. Carlos Caldas
    You can also search for this author inPubMed Google Scholar
  18. Nitzan Rosenfeld
    You can also search for this author inPubMed Google Scholar

Contributions

M.M., S.-J.D., T.F., D.W.Y.T., D.G., J.D.B., C.C. and N.R. designed the study. M.M., D.W.Y.T. and T.F. developed methods. S.-J.D., C.P., A.S.C.W., T.M.C., J.D.B. and C.C. designed and conducted the prospective clinical studies. M.M., S.-J.D., D.W.Y.T., D.G., T.F. and A.M.P. generated data. Z.K., S.H. and D.B. contributed sequencing data. M.M., F.M. and N.R. analysed sequencing data. S.-F.C. and J.H. contributed to experiments and data analysis. M.M., S.-J.D., D.W.Y.T., T.M.C., J.D.B., C.C. and N.R. interpreted data. M.M. and N.R. wrote the paper with assistance from S.-J.D., D.W.Y.T., C.C., J.D.B. and other authors. All authors approved the final manuscript. J.D.B., C.C. and N.R. are the project co-leaders and joint senior authors.

Corresponding authors

Correspondence toJames D. Brenton, Carlos Caldas or Nitzan Rosenfeld.

Ethics declarations

Competing interests

Z.K., S.H. and D.B. are full-time employees of Illumina, Inc., providers of the sequencing technology used in this study; the other authors declare no competing financial interests.

Supplementary information

Supplementary Information

This file contains Supplementary Text, Supplementary Figures 1-8 and Supplementary Tables 1-3. (PDF 2709 kb)

Supplementary Tables

This file contains Supplementary Tables 4-9, which contain a list of mutations with increased representation in plasma over the course of treatment for Cases 1-6. (XLSX 103 kb)

PowerPoint slides

Rights and permissions

About this article

Cite this article

Murtaza, M., Dawson, SJ., Tsui, D. et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA.Nature 497, 108–112 (2013). https://doi.org/10.1038/nature12065

Download citation